Funding for this research was provided by:
Welsh Clinical Academic Training (WCAT) Scheme
Association of Clinical Pathologists (Career Development Award)
UKRI (UKRI COVID-19 National Core Study Immunity programme (‘SARS-CoV-2 Optimal Cellular Assays’), UKRI COVID-19 National Core Study Immunity programme (‘SARS-CoV-2 Optimal Cellular Assays’))
Innovate UK (SBRI award (‘Assays for SARS-CoV-2 cellular immune responses'), SBRI award (‘Assays for SARS-CoV-2 cellular immune responses'))
Cancer Research Wales (Support for AG, MJS)
Wellcome Trust (209213/Z/17/Z)
Received: 15 September 2021
Accepted: 13 October 2021
First Online: 29 October 2021
: Written informed consent to participate in the COVID-19 ENLIST study (REC 20/YH/0309) was provided by the individual.
: SJ has received support for conferences, speaker, advisory boards, trials, data and safety monitoring boards, and projects with CSL Behring, Takeda, Swedish Orphan Biovitrum, Biotest, Binding Site, Grifols, BPL, Octapharma, LFB, Pharming, GSK, Weatherden, Zarodex, Sanofi, and UCB Pharma. None of these conflicts relates to the current work. TE has received support for education, speaker, advisory boards, and/or research from Allergy Therapeutics, CSL Behring, Mylan, Novartis, Pharming, Takeda, and Thermo Fisher. MJS is a founder of and holds equity in ImmunoServ Ltd. The remaining authors have no potential relevant conflicts of interests to declare.